-
1
-
-
84897078555
-
-
Accessed October 20, 2014
-
American Cancer Society. Cancer Facts and Figures 2014. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed October 20, 2014.
-
(2014)
Cancer Facts and Figures
-
-
-
2
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
3
-
-
0031800885
-
EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma
-
C. Messa, F. Russo, M.G. Caruso, and et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma Acta Oncol 37 1998 285 289
-
(1998)
Acta Oncol
, vol.37
, pp. 285-289
-
-
Messa, C.1
Russo, F.2
Caruso, M.G.3
-
4
-
-
0027415146
-
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
-
A. Mayer, M. Takimoto, E. Fritz, and et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer 71 1993 2454 2460
-
(1993)
Cancer
, vol.71
, pp. 2454-2460
-
-
Mayer, A.1
Takimoto, M.2
Fritz, E.3
-
5
-
-
70450195266
-
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
-
N. Normanno, S. Tejpar, F. Morgillo, and et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 519-527
-
-
Normanno, N.1
Tejpar, S.2
Morgillo, F.3
-
6
-
-
77949435827
-
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
-
A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
-
(2010)
J Clin Oncol
, vol.28
, pp. 1254-1261
-
-
Bardelli, A.1
Siena, S.2
-
7
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
C. Bokemeyer, I. Bondarenko, A. Makhson, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
8
-
-
0036848820
-
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice
-
D. Kedar, C.H. Baker, J.J. Killion, and et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice Clin Cancer Res 8 2002 3592 3600
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3592-3600
-
-
Kedar, D.1
Baker, C.H.2
Killion, J.J.3
-
9
-
-
0035394833
-
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis
-
A. Viloria-Petit, T. Crombet, S. Jothy, and et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 2001 5090 5101
-
(2001)
Cancer Res
, vol.61
, pp. 5090-5101
-
-
Viloria-Petit, A.1
Crombet, T.2
Jothy, S.3
-
10
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
S.M. Wilhelm, L. Adnane, P. Newell, and et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
-
11
-
-
77958058348
-
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
-
E. Martinelli, T. Troiani, F. Morgillo, and et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells Clin Cancer Res 16 2010 4990 5001
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4990-5001
-
-
Martinelli, E.1
Troiani, T.2
Morgillo, F.3
-
12
-
-
35648941728
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
-
L.B. Saltz, H.J. Lenz, H.L. Kindler, and et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
-
(2007)
J Clin Oncol
, vol.25
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.J.2
Kindler, H.L.3
-
13
-
-
84860124769
-
Panitumumab: a summary of clinical development in colorectal cancer and future directions
-
G. Argiles, R. Dienstmann, E. Elez, and et al. Panitumumab: a summary of clinical development in colorectal cancer and future directions Future Oncol 8 2012 373 389
-
(2012)
Future Oncol
, vol.8
, pp. 373-389
-
-
Argiles, G.1
Dienstmann, R.2
Elez, E.3
-
14
-
-
84876734927
-
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
-
S. Bhattacharyya, K. Kurdziel, L. Wei, and et al. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas Nucl Med Biol 40 2013 451 457
-
(2013)
Nucl Med Biol
, vol.40
, pp. 451-457
-
-
Bhattacharyya, S.1
Kurdziel, K.2
Wei, L.3
-
15
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
16
-
-
77957966490
-
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry
-
L. Li, M. Zhao, F. Navid, and et al. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 3033 3038
-
(2010)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.878
, pp. 3033-3038
-
-
Li, L.1
Zhao, M.2
Navid, F.3
-
17
-
-
24644442153
-
A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma
-
C.H. Druzgal, Z. Chen, N.T. Yeh, and et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma Head Neck 27 2005 771 784
-
(2005)
Head Neck
, vol.27
, pp. 771-784
-
-
Druzgal, C.H.1
Chen, Z.2
Yeh, N.T.3
-
18
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
19
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
20
-
-
44449142019
-
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
-
H. Minami, K. Kawada, H. Ebi, and et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors Cancer Sci 99 2008 1492 1498
-
(2008)
Cancer Sci
, vol.99
, pp. 1492-1498
-
-
Minami, H.1
Kawada, K.2
Ebi, H.3
-
21
-
-
64649083367
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
-
A.A. Miller, D.J. Murry, K. Owzar, and et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 J Clin Oncol 27 2009 1800 1805
-
(2009)
J Clin Oncol
, vol.27
, pp. 1800-1805
-
-
Miller, A.A.1
Murry, D.J.2
Owzar, K.3
-
22
-
-
84864361013
-
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
-
N. Pecuchet, C. Lebbe, O. Mir, and et al. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer 107 2012 455 461
-
(2012)
Br J Cancer
, vol.107
, pp. 455-461
-
-
Pecuchet, N.1
Lebbe, C.2
Mir, O.3
-
23
-
-
79960151990
-
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
-
L. Jain, S. Woo, E.R. Gardner, and et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours Br J Clin Pharmacol 72 2011 294 305
-
(2011)
Br J Clin Pharmacol
, vol.72
, pp. 294-305
-
-
Jain, L.1
Woo, S.2
Gardner, E.R.3
-
24
-
-
20344362911
-
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
-
A. Awada, A. Hendlisz, T. Gil, and et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 2005 1855 1861
-
(2005)
Br J Cancer
, vol.92
, pp. 1855-1861
-
-
Awada, A.1
Hendlisz, A.2
Gil, T.3
-
25
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
J.R. Hecht, E. Mitchell, T. Chidiac, and et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
-
(2009)
J Clin Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
-
26
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
J. Tol, M. Koopman, A. Cats, and et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
-
27
-
-
77953641347
-
Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (the BOND 2.5 study)
-
N.H. Segal, D. Reidy-Lagunes, M. Capanu, and et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (the BOND 2.5 study) J Clin Oncol 27 15 suppl 2009 abstract 4087
-
(2009)
J Clin Oncol
, vol.27
, Issue.15
-
-
Segal, N.H.1
Reidy-Lagunes, D.2
Capanu, M.3
-
28
-
-
84877755368
-
Mechanisms of resistance to anti-angiogenesis therapies
-
S. Giuliano, and G. Pages Mechanisms of resistance to anti-angiogenesis therapies Biochimie 95 2013 1110 1119
-
(2013)
Biochimie
, vol.95
, pp. 1110-1119
-
-
Giuliano, S.1
Pages, G.2
-
29
-
-
49849084552
-
Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
-
X. Li, Y. Lu, K. Liang, and et al. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab Mol Cancer Ther 7 2008 1207 1217
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1207-1217
-
-
Li, X.1
Lu, Y.2
Liang, K.3
-
31
-
-
75749096309
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
-
S. Kopetz, P.M. Hoff, J.S. Morris, and et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
-
(2010)
J Clin Oncol
, vol.28
, pp. 453-459
-
-
Kopetz, S.1
Hoff, P.M.2
Morris, J.S.3
-
32
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
E. Van Cutsem, C.H. Kohne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
-
33
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
B. Escudier, T. Eisen, W.M. Stadler, and et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
34
-
-
79953301961
-
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism
-
E. Bellini, A. Pia, M.P. Brizzi, and et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism Ann Oncol 22 2011 988 990
-
(2011)
Ann Oncol
, vol.22
, pp. 988-990
-
-
Bellini, E.1
Pia, A.2
Brizzi, M.P.3
-
35
-
-
84855177596
-
Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications
-
O. Mir, R. Coriat, P. Boudou-Rouquette, and et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications Ann Oncol 23 2012 280 281
-
(2012)
Ann Oncol
, vol.23
, pp. 280-281
-
-
Mir, O.1
Coriat, R.2
Boudou-Rouquette, P.3
-
36
-
-
80052458543
-
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
-
D.P. Modest, S. Stintzing, R.P. Laubender, and et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status Anticancer Drugs 22 2011 913 918
-
(2011)
Anticancer Drugs
, vol.22
, pp. 913-918
-
-
Modest, D.P.1
Stintzing, S.2
Laubender, R.P.3
-
37
-
-
78049341541
-
Association of KRAS P.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS P.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
38
-
-
84867117207
-
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
-
S. Tejpar, I. Celik, M. Schlichting, and et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 2012 3570 3577
-
(2012)
J Clin Oncol
, vol.30
, pp. 3570-3577
-
-
Tejpar, S.1
Celik, I.2
Schlichting, M.3
-
39
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
40
-
-
84925300141
-
Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (MCRC)
-
M. Schirripa, S. Lonardi, C. Cremolini, and et al. Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (MCRC) Ann Oncol 25 suppl 2 2014 ii6 7
-
(2014)
Ann Oncol
, vol.25
, pp. ii6-ii7
-
-
Schirripa, M.1
Lonardi, S.2
Cremolini, C.3
|